Assessment of the hypoglycemic effect of Bixin in alloxan-induced diabetic rats: <i>in vivo</i> and <i>in silico</i> studies
Hady Keita, Cleydson B. R. Santos, Matheus Mercês Ramos, Elias Carvalho Padilha, Rodolfo Bortolozo Serafim, Andrés Navarrete, Jesús Rafael Rodríguez Amado, Gabriel Monteiro da Silva, Irlon M. Ferreira, Silvana Giuliatti, José Carlos Tavares Carvalho
Abstract
tests. Bixin may act by other pathways to control blood glucose and thus it is possible that it presents a different toxicity profile than troglitazone, rosiglitazone and pioglitazone. However, more studies on the activity and toxicity of Bixin are needed to evaluate for further clinical use. Communicated by Ramaswamy H. Sarma.
Topics & Concepts
In silicoPioglitazoneIn vivoRosiglitazonePharmacologyChemistryPeroxisome proliferator-activated receptorAlloxanTroglitazoneReceptorPeroxisomeBiochemistryDiabetes mellitusBiologyEndocrinologyType 2 diabetesGeneBiotechnologyPeroxisome Proliferator-Activated ReceptorsMetabolism, Diabetes, and CancerNatural Products and Biological Research